Top 20 Pharmaceutical Firms / Revenue 2022 & Market Cap 2023
Michael Meegan
Strategic Recruitment Partner at SearchMode - Life Sciences| Consumer| Manufacturing| Technology ???? GCC / MENA Talent Acquisition, Executive Search & Headhunting Enthusiast ???? 37k + followers
For the first time in biopharma history, a firm has topped the $100 billion mark in annual revenue.?Pfizer passed?that milestone, propelled by its massive haul from its COVID-19 products. Its BioNTech-partnered vaccine, Comirnaty, raked in $37.8 billion, and oral antiviral Paxlovid made $18.9 billion.
Subtract the COVID treatments from Pfizer’s top line and its revenue would be $43 billion, which is right in line with the firms pre-pandemic sales. The Big Pharma's sales gradually increased from $40.8 billion in 2018 to $41.6 billion in 2020.
With its windfall, Pfizer displaced Johnson & Johnson as the industry’s No. 1 revenue generator. J&J had occupied that position for a decade and had been closing in on the $100 billion mark. Sales for 2021 and 2022 came in at $93.8 billion and $94.9 billion, respectively.
But with J&J on the verge of separating from its consumer health business, its overall revenue will take a tumble. The unit, dubbed Kenvue, accounted for $15 billion of J&J’s sales last year.?
It might be a while before a company tops the $100 billion mark again. With sales of COVID products expected to decline sharply, Pfizer is projecting its revenue to come in at between $67 billion and $71 billion in 2023.
Pfizer had a gaudy 23% revenue increase over 2021, the second largest jump among the top 20 revenue generators. The top gain was registered by Novo Nordisk, which saw a 26% surge,?owed largely to demand for its diabetes and obesity products Ozempic and Wegovy.
The only other companies in this heady territory were Merck, with a 22% increase, and AstraZeneca, with an 18% boost.
Merck rode the coattails of cancer superstar Keytruda, which rang up $20.9 billion, and COVID oral antiviral Lagevrio, which pulled in $5.7 billion. AZ owes its growth largely to $2.2 billion in sales of short-lived COVID antibody Evusheld plus major sales gains from blockbusters Calquence, Farxiga and Ultomiris.
Right behind Merck, which ranked No. 4 in revenue, was No. 5 AbbVie, which also was propelled by a single megablockbuster. Generating $21.2 billion in sales, Humira accounted for 35.6% of AbbVie’s revenue, compared to Keytruda’s 35.2% share of Merck’s sales.
The lone companies that saw a significant revenue decline were GSK (11%) and BioNTech (9%). GSK's decrease can be chalked up to its separation from consumer health unit Haleon, which reported sales of 10.9 billion pounds sterling ($13.4 billion). Take Haleon out of the equation, and GSK actually had a healthy revenue gain.
BioNTech's revenue drop came from declining sales of its lone commercial product, the Comirnaty vaccine it shares with Pfizer.
Small revenue declines were registered by Novartis (2%), Bristol Myers Squibb (0.5%) and Gilead Sciences (0.1%).
Falling out of the top 20 from last year is Viatris, which saw a 9% revenue decline in 2022, continuing a sales slide that began in 2020. Entering the top 20 is Merck KGaA on the strength of a 13% sales increase.
1.Pfizer
2022 revenue:?$100.33b
2021 revenue:?$81.29b
Market Cap 2023: $226.96b
2. Johnson & Johnson
2022 revenue:?$94.94b
2021 revenue:?$93.77b
Market Cap 2023: $510.84b
3. Roche
2022 revenue: $66.26b
2021 revenue:?$62.80b
Market Cap 2023: $253.84b
4. Merck
2022 revenue: $59.28 billion
2021 revenue: $48.70 billion
Market Cap 2023 : $289.93b
5. Abbvie
2022 revenue:?$58.05 billion
2021 revenue:?$56.20 billion
Market Cap 2023: $287.45b
6. Novartis
2022 revenue:?$50.54 billion
2021 revenue:?$51.63 billion
Market Cap 2023: $212.59b
7. Bristol Myers Squibb
2022 revenue:?$46.16 billion
2021 revenue:?$46.38 billion
Market Cap: $147.53 billion
8. Sanofi
2022 revenue:?$45.22 billion
2021 revenue:?$44.63 billion
Market Cap 2023: $142.83b
9. AstraZeneca
2022 revenue:?$44.35 billion
2021 revenue:?$37.42 billion
Market Cap 2023: $234.33b
10. GSK
2022 revenue:?$36.15 billion
领英推荐
2021 revenue:?$46.92 billion
Market Cap 2023: $75.16b
11. Takeda
2022 revenue:?$30.00 billion
2021 revenue:?$31.57 billion
Market Cap 2023: $52.88b
12. Eli Lilly
2022 revenue:?$28.55 billion
2021 revenue:?$28.32 billion
Market Cap 2023: $356.18b
13. Gilead
2022 revenue:?$27.28 billion
2021 revenue:?$27.30 billion
Market Cap 2023: $105.76b
14. Bayer
2022 revenue:?$26.64 billion
2021 revenue:?$27.94 billion
Market Cap 2023: $65.46b
15. Amgen
2022 revenue:?$26.32 billion
2021 revenue:?$25.98 billion
Market Cap 2023: $130.27b
16. Boehringer Ingelheim
2022 revenue:?$25.28 billion
2021 revenue:?$24.24 billion
Market Cap: privately owned
17. Novo Nordisk
2022 revenue:?$25.00 billion
2021 revenue:?$22.38 billion
Market Cap 2023: $388.18b
18. Moderna
2022 revenue:?$19.26 billion
2021 revenue:?$18.47 billion
Market Cap 2023: $54.32b
19. Merck KGaA
2022 revenue:?$19.16 billion
2021 revenue:?$19.11 billion
Market Cap 2023: $77.08b
20. BioNTech
2022 revenue:?$18.20 billion
2021 revenue:?$22.43 billion
Market Cap: $28.50 billion
Medical Director, North America Medical Affairs, CSL Behring
1 年Great article …
Country Head Gulf Countries | Executive MBA, OTC Markets Expert
1 年Informative and to the point…thanks Michael
Senior Medical Sales Executive @ Globalpharma LLC | MBA | Business Development | Pharmaceuticals
1 年Very helpful ??
Pharma Business Leader | I coach and mentor mid-career professionals on how to make a progressive career in the pharmaceuticals industry, create impact and take charge of their promotions
1 年Very informative article, thanks for sharing Michael!
E2E Supply Chain Strategy & Operations | Pharmaceutical | Active Pharmaceutical Ingredients | Consumer Health & FMCG | SCMC CoE @ IIMB | Management Consulting | India | GCC, Levant, Iran, Iraq | AfMET
1 年Very informative.